GIP receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-26. Anything still debated is marked as such rather than presented as settled.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
The structure of histatin is unique depending on whether the protein of interest is histatin 1, 3 or 5. Nonetheless, histatins mainly possess a cationic (positive) charge due to the primary structure consisting mostly of basic amino acids. An amino acid that is crucial to histatin's function is histidine. Studies show that the removal of histidine (especially in histatin 5) resulted in reduction of antifungal activity.
== Disorders == Bradykinin is also thought to be the cause of the dry cough in some patients on widely prescribed angiotensin-converting enzyme (ACE) inhibitor drugs. It is thought that bradykinin is converted to inactive metabolites by ACE, therefore inhibition of this enzyme leads to increased levels of bradykinin; increased bradykinin sensitizes somatosensory fibers and thus causes hyperalgesia. Bradykinin may mediate this via pro-inflammatory peptides (e.g. substance P, neuropeptide Y) and a local release of histamine. In severe cases, the elevation of bradykinin may result in angioedema, a medical emergency. People of African descent have up to five times increased risk of ACE inhibitor induced angioedema due to hereditary predisposing risk factors such as hereditary angioedema. This refractory cough is a common cause for stopping ACE inhibitor therapy. Overactivation of bradykinin is thought to play a role in a rare disease called hereditary angioedema. Low levels of bradykinin in the body correlate with obesity in adolescents; it has been proposed that bradykinin can be used as a biomarker for metabolic syndrome. Bradykinins have been implicated in a number of cancer progression processes. Increased levels of bradykinins resulting from ACE inhibitor use have been associated with increased lung cancer risks. Bradykinins have been implicated in cell proliferation and migration in gastric cancers, and bradykinin antagonists have been investigated as anti-cancer agents.
=== Peripheral appetite signaling/gastric sensorimotor function === Mechanisms of weight loss from ESG remains an area of active study. There are at least two mechanisms of peripheral appetite signaling thought to be mediated by ESG: first, increased sense of fullness during a meal leading to meal termination, potentially a result of the intact gastric fundus that serves as a food reservoir and the restriction to gastric expansion (accommodation) during a meal; and second, from delayed emptying of the stomach, which promotes a prolonged sensation of fullness after a meal.
== Prognosis == Prognosis depends on the condition itself. Some conditions such as MS depend on the subtype of the disease and various attributes of the patient such as age, sex, initial symptoms, and the degree of disability the patient experiences. Life expectancy in MS patients is 5 to 10 years lower than unaffected people. MS is an inflammatory demyelinating disease of the central nervous system (CNS) that develops in genetically susceptible individuals after exposure to unknown environmental trigger(s). The bases for MS are unknown but are strongly suspected to involve immune reactions against autoantigens, particularly myelin proteins. The most accepted hypothesis is that dialogue between T-cell receptors and myelin antigens leads to an immune attack on the myelin-oligodendrocyte complex. These interactions between active T cells and myelin antigens provoke a massive destructive inflammatory response and promote continuing proliferation of T and B cells and macrophage activation, which sustains secretion of inflammatory mediators. Other conditions such as central pontine myelinolysis have about a third of patients recover and the other two-thirds experience varying degrees of disability. In some cases, such as transverse myelitis, the patient can begin recovery as early as 2 to 12 weeks after the onset of the condition.
The date, published the next day, shows that almost 184,000 people in Scotland identify as LGBT. Officials confirm that the first batch of prisoners to be released early from prison in order to free up prison spaces have been freed. 28 June – Edinburgh City Council establishes an emergency polling booth at City Chambers after a number of people across Scotland reported not receiving their postal votes. The emergency polling booth, which allows those who did not receive a postal vote to cast their vote in person, will operate until 30 June. Fife Council also announces an emergency polling booth at Fife House, Glenrothes that will be open on 29 June. The final two second generation Glasgow Subway trains are taken out of service following the rollout of new third generation vehicles. 29 June – East Lothian Council becomes the third local authority to establish an emergency facility for people who have not received their postal votes.
Sources: en.wikipedia.org
== Gastroenterology == In gastroenterology, the term overlap syndrome may be used to describe autoimmune liver diseases that combine characteristic features of autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis.
== Diagnostic use == Serum creatinine is the most commonly used indicator (although not a direct measure) of renal function. A raised creatinine is not always representative of a true reduction in GFR. A high reading may be due to: increased production of creatinine (with no association to reduced kidney function), interference with the assay, or reduced tubular secretion of creatinine. An increase in serum creatinine can be due to increased ingestion of cooked meat (which contains creatinine converted from creatine by the heat from cooking) or excessive intake of protein and creatine supplements, taken to enhance athletic performance. Intense exercise can increase creatinine by increasing muscle breakdown. Hypovolaemia of any cause, may have an associated increase in creatinine concentration, secondary to the expected reduction in GFR. This is pre-renal impairment of kidney function. Several medications and chromogens can interfere with the chemical assay. Creatinine secretion by the renal tubules can be blocked by some medications, again increasing measured creatinine.
=== Similar species === Several species may be confused with A. campestris. The most dangerous confusion may be with the deadly Amanita virosa (a 'destroying angel') or the deadly Amanita hygroscopica (pink-gilled destroying angel). Amanita species may be distinguished from Agaricus by a volva at the base, remnants of a universal veil. Such a veil may also be seen surrounding adjacent smaller button mushrooms, if present. It's recommended to look for smaller sibling buttons nearby, and slice one of them lengthwise to examine their anatomy. They may also be distinguished by a white or off-white spore print while mushrooms in the family Agaricacea are dark brown. In the United States, the poisonous Agaricus californicus and A. hondensis may be similar. White Clitocybe species that also grow in grassy places may be toxic. A less serious, but more common, confusion is with Agaricus xanthodermus (the yellow stainer), which causes gastrointestinal problems in many people. A. arvensis (the horse mushroom) is very similar and is an excellent edible. It is nearly identical (except microscopically) to the edible species Agaricus andrewii and A. solidipes.
The optical lens has been playing a critical role in almost all areas of science and technology since its invention about 3000 years ago. With the advances in micro- and nanofabrication techniques, continued miniaturization of the conventional optical lenses has always been requested for various applications such as communications, sensors, data storage and a wide range of other technology-driven and consumer-driven industries. Specifically, ever smaller sizes, as well as thinner thicknesses of micro lenses, are highly needed for subwavelength optics or nano-optics with extremely small structures, particularly for visible and near-IR applications. Also, as the distance scale for optical communications shrinks, the required feature sizes of micro lenses are rapidly pushed down. Recently, the excellent properties of newly discovered graphene oxide provide novel solutions to overcome the challenges of current planar focusing devices. Specifically, giant refractive index modification (as large as 10^-1), which is one order of magnitude larger than the current materials, between graphene oxide (GO) and reduced graphene oxide (rGO) have been demonstrated by dynamically manipulating its oxygen content using the direct laser writing (DLW) method. As a result, the overall lens thickness can be potentially reduced by more than ten times. Also, the linear optical absorption of GO is found to increase as the reduction of GO deepens, which results in transmission contrast between GO and rGO and therefore provides an amplitude modulation mechanism.
Relief Therapeutics is a Swiss biopharmaceutical company based in Geneva. The company focuses on developing drugs for serious diseases with few or no existing treatment options. Its lead compound, RLF-100, is a synthetic form of a natural peptide that protects the lung. The company was incorporated as Relief Therapeutics Holdings AG (RFLB.S) and listed on the SIX Swiss Exchange in 2016.
Sources: en.wikipedia.org
== See also == Areas annexed by Nazi Germany British Committee for Refugees from Czechoslovakia Flight and expulsion of Germans (1944–1950) Republic of German-Austria Germans in Czechoslovakia (1918–1938) Pursuit of Nazi collaborators Sudetenland Medal
=== Fifth Republic === December 23, 1958: Decree amending various criminal provisions to introduce a fifth class of police contraventions; notably punishes passive soliciting. December 30, 1958: The term "birth allowance" replaces "maternity allowance," and the conditions for both that and the single wage allowance are modified. February 4, 1959: Ordinance on the general status of civil servants, which includes the principle of non-discrimination based on sex, except in certain exceptional cases, notably in the national police. April 9, 1960: Decree concerning the family record book. November 25, 1960: Ordinance on the fight against pimping. November 25, 1960: By decree, passive soliciting becomes a 3rd-class offense, active soliciting a 5th-class offense. December 2, 1960: France ratifies the United Nations Convention for the Suppression of the Traffic in Persons and of the Exploitation of the Prostitution of Others; the sanitary and social registry of prostitutes — created by law on April 24, 1946, and listing about 30,000 people in 1960 — is abolished. July 13, 1965: Law reforming matrimonial regimes: modification of the legal regime for marriages without a contract: the wife is free to manage her own property and pursue professional activity, no longer needing her husband's consent. September 29, 1965: Order establishing a study and liaison committee on women's labor issues. July 11, 1966: Law reforming adoption. December 30, 1966: Law on job protection in cases of maternity.
==== Comment about drug traffickers ==== On 24 October 2025, president Lula made a controversial statement during an interview with the press in Jakarta, Indonesia, at the end of his visit to the Asian country. Asked about statements by Donald Trump, the president stated that traffickers are "victims of users" and suggested that it would be "easier", for both Brazil and the United States, to "combat addicts". Lula's statement, made during the early hours in Brasília time, had wide negative repercussions and was the target of criticism from opposition parliamentarians. On the same day, hours after the repercussions, Lula retracted on X (formerly Twitter) and stated that his declaration had been a "poorly worded sentence".
=== Non-competitive === In non-competitive inhibition the binding of the inhibitor to the enzyme reduces its activity but does not affect the binding of substrate. This type of inhibitor binds with equal affinity to the free enzyme as to the enzyme-substrate complex. It can be thought of as having the ability of competitive and uncompetitive inhibitors, but with no preference to either type. As a result, the extent of inhibition depends only on the concentration of the inhibitor. Vmax will decrease due to the inability for the reaction to proceed as efficiently, but Km will remain the same as the actual binding of the substrate, by definition, will still function properly.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It is normally kept frozen, desiccated, and away from light, with brief warming to room temperature before opening to limit condensation. Repeated freeze-thaw cycles are avoided because they stress the peptide. Once in solution, the material is held cold and used promptly.